Curebase Hires Health Tech Veteran Scott Garcia as VP of Finance

Former Dr. Evidence CFO brings over 15 years of experience to new role

SAN FRANCISCO, May 24, 2022 /PRNewswire/ — Curebase, a company committed to democratizing access to clinical trials, today announced the appointment of Scott Garcia as vice president of finance. In his new role, Garcia will guide Curebase’s strategic financial and operational direction, centralize its financial and accounting functions while implementing industry standard internal controls, and provide communications to financial stakeholders.

Upload a photo of Scott GarciaClick here.

Previously, Garcia served as CFO at Dr.Evidence, the leading medical intelligence platform for life science companies that enables users to identify breakthrough insights based on the vast universe of published medical information, real-world evidence and proprietary data.

Garcia is an experienced health tech veteran with a relentless focus on growth, innovation and brings over 15 years of financial experience scaling high-growth businesses to Curebase. Garcia served as a strategic partner to executive management and boards of directors, supporting their execution on short- and long-term goals to maximize shareholder value.

Garcia has deep experience in a number of key financial skills, including: financial and operational planning, modeling and analysis; building and cultivating teams for long-term success; refine processes and systems through automation to improve the efficiency and effectiveness needed to scale high-growth businesses; and manage relationships with regulators, external auditors, and tax and legal professionals.

Prior to Dr. Evidence, Garcia served as Vice President of Finance for RGM Group and Chief Audit Executive at Holthouse Carlin & Van Trigt LLP, a national accounting firm.

“I am thrilled to join the incredible leadership team at Curebase,” said Garcia. “I look forward to collaborating with some of the brightest minds in the industry as we continue to emerge as a leader in decentralized clinical trials with our end-to-end clinical trial execution powered by cutting-edge technology.”

“We are thrilled to welcome an experienced and innovative finance leader like Scott to the team,” said Tom Lemberg, founder and CEO of Curebase. “His talents and strategic advice will be essential as Curebase enters its next stage of domestic and international growth and development.”

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human well-being through more effective clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians around the world to recruit patients from the communities where they live. By applying state-of-the-art clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up. For more information, please visit www.curebase.com.

For more information, please contact:
Shawn MalloyCurebase
Phone: 315-882-5310
E-mail: [email protected]

SOURCE Curebase

Comments are closed.